Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Not Yet Opened 11-25 16:00:00 EST

28.14

+1.12

+4.15%

盘后28.14

+0.000.00%

17:08 EST

High28.40	Low27.34	Vol946.61K
Open27.88	D1 Closing27.02	Amplitude3.92%
Mkt Cap1.87B	Tradable Cap1.76B	Total Shares66.34M
T/O26.55M	T/O Rate1.51%	Tradable Shares62.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":28.14,"timestamp":1732568400000,"preClose":27.02,"halted":0,"volume":946607,"hourTrading":{"tag":"盘后","latestPrice":28.14,"preClose":28.14,"latestTime":"17:08 EST","volume":24325,"amount":684457.4045,"timestamp":1732572525457},"delay":0,"floatShares":62701121,"shares":66344236,"eps":-2.533348,"marketStatus":"Not Yet Opened","change":1.12,"latestTime":"11-25 16:00:00 EST","open":27.879,"high":28.4,"low":27.34,"amount":26554997.674954,"amplitude":0.03923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.533348,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":27.02,"preHourTrading":{"tag":"盘前","latestPrice":27.41,"preClose":27.02,"latestTime":"09:29 EST","volume":525,"amount":14376.4404,"timestamp":1732544999999},"postHourTrading":{"tag":"盘后","latestPrice":28.14,"preClose":28.14,"latestTime":"17:08 EST","volume":24325,"amount":684457.4045,"timestamp":1732572525457},"volumeRatio":1.043736,"impliedVol":0.6045,"impliedVolPercentile":0.623},"requestUrl":"/m/hq/s/CLDX","defaultTab":"news","newsList":[{"id":"2485381174","title":"Insider Spends US$308k Buying More Shares In Celldex Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2485381174","media":"Simply Wall St.","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485381174?lang=en_us&edition=fundamental","pubTime":"2024-11-21 02:31","pubTimestamp":1732127486,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) should definitely note that the Founder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/insider-spends-us308k-buying-more-shares-in-celldex-therapeu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2484111109","title":"Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2484111109","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484111109?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:56","pubTimestamp":1732110962,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics  said Wednesday that the first patient has been dosed in the company's phase 1a study of CDX-622, a potential inflammatory disease treatment, in healthy volunteers.The drug is an antibody that targets two complementary pathways that drive inflammatory diseases by neutralizing thymic stromal lymphopoietin and depleting mast cells, the company said.The phase 1a study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses and multiple ascending doses of CDX-622 in up to 56 healthy participants, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2484111580","title":"BRIEF-Celldex Announces First Patient Dosed In Phase 1 Healthy Volunteer Study Of CDX-622","url":"https://stock-news.laohu8.com/highlight/detail?id=2484111580","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484111580?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:07","pubTimestamp":1732108069,"startTime":"0","endTime":"0","summary":"BRIEF-Celldex Announces First Patient Dosed In Phase 1 Healthy Volunteer Study Of CDX-622Nov 20 (Reuters) - Celldex Therapeutics Inc CLDX.O:CELLDEX ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 HEALTHY VOL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8ZV6VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2484113263","title":"Celldex Therapeutics Inc - Subcutaneous Formulation to Be Added to Study in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2484113263","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484113263?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:01","pubTimestamp":1732107660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8ZV6VD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2484113255","title":"Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of Cdx-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2484113255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484113255?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:01","pubTimestamp":1732107660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8ZV6VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2484115844","title":"Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2484115844","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484115844?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:01","pubTimestamp":1732107660,"startTime":"0","endTime":"0","summary":"HAMPTON, N.J., Nov.  20, 2024  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/20/2984404/24180/en/Celldex-Announces-First-Patient-Dosed-in-Phase-1-Healthy-Volunteer-Study-of-CDX-622-a-Bispecific-Antibody-for-the-Treatment-of-Inflammatory-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP","BK4139","CDX","CLDX"],"gpt_icon":0},{"id":"2484199285","title":"Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484199285","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484199285?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:21","pubTimestamp":1732101660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 06:21 ET (11:21 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2483780503","title":"Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2483780503","media":"GuruFocus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483780503?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:58","pubTimestamp":1731675504,"startTime":"0","endTime":"0","summary":"Overview of the Recent Transaction On September 30, 2024, the investment firm led by Steven Cohen (Trades, Portfolio) executed a significant transaction involving Celldex Therapeutics Inc (CLDX, Finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2606081/steven-cohens-strategic-reduction-in-celldex-therapeutics-holdings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2481712413","title":"Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2481712413","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481712413?lang=en_us&edition=fundamental","pubTime":"2024-11-08 18:29","pubTimestamp":1731061787,"startTime":"0","endTime":"0","summary":"NasdaqCM:CLDX Earnings and Revenue Growth November 8th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 197%. Earnings per share  also surpassed analyst estimates by 5.4%.Looking ahead, revenue is forecast to grow 88% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are up 1.6% from a week ago.You should always think about risks. Case in point, we've spotted   3 warning signs for Celldex Therapeutics  you should be aware of, and 1 of them is concerning.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-therapeutics-third-quarter-2024-102947507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLDX"],"gpt_icon":0},{"id":"2481156512","title":"Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481156512","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481156512?lang=en_us&edition=fundamental","pubTime":"2024-11-08 04:25","pubTimestamp":1731011100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2024 15:25 ET (20:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2481845771","title":"Celldex Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481845771","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481845771?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:09","pubTimestamp":1730992184,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary  Celldex Therapeutics Inc CLDX.OQ reported a quarterly adjusted loss of 64 cents per share for the qua","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL8N3ME2SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2481902541","title":"Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481902541?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:19","pubTimestamp":1730985580,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Celldex (CLDX – Research Report), with a price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-celldex-cldx-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-celldex-cldx-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2481960091","title":"Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481960091","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481960091?lang=en_us&edition=fundamental","pubTime":"2024-11-07 06:30","pubTimestamp":1730932205,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics  came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.59 per share when it actually produced a loss of $0.54, delivering a surprise of 8.47%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Celldex , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.19 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 121.60%. This compares to year-ago revenues of $1.52 million. The company has topped consensus revenue estimates three times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a mat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-therapeutics-cldx-reports-q3-223005164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLDX"],"gpt_icon":0},{"id":"2481957975","title":"Celldex: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481957975","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481957975?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:25","pubTimestamp":1730928328,"startTime":"0","endTime":"0","summary":"HAMPTON, N.J.  — HAMPTON, N.J.  — Celldex Therapeutics Inc.  on Wednesday reported a loss of $42.1 million in its third quarter.On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 64 cents.The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 69 cents per share.The biopharmaceutical company posted revenue of $3.2 million in the period, also surpassing Street forecasts. Three analysts surveyed by Zacks expected $1.4 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-q3-earnings-snapshot-212528812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLDX"],"gpt_icon":0},{"id":"2481778956","title":"Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481778956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481778956?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:01","pubTimestamp":1730926909,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA6MVHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2481716956","title":"Celldex Therapeutics Q3 Revenue USD 3.191 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481716956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481716956?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:01","pubTimestamp":1730926909,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nPLX3B43C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2481908954","title":"Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481908954","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481908954?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:01","pubTimestamp":1730926860,"startTime":"0","endTime":"0","summary":"Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentAll primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2976017/24180/en/Celldex-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","SD","BK4139","BK4213","TSLP"],"gpt_icon":0},{"id":"2481762786","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2481762786","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481762786?lang=en_us&edition=fundamental","pubTime":"2024-11-06 19:00","pubTimestamp":1730890800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEVA","BATRA","EHAB","CXDO","CHRD","CURI","ASH","BIRD","COYA","EBS","INTC","PLUS","CXT","TSM","EVO","LAW","ALNT","BAK","ET","ABUS","EVTC","NVDA","QCOM","OBDC","ALB","BKD","ERAS","AAPL","BIP","ASPN","BWMN","CLBT","ACLS","AEE","ASML","AMZN","ASC","BATRK","CHT","BROS","AADI","CERT","EFC","COHR","AMD","ALTG","MSFT","APP","CLDX","EHTH","AUDC","BHVN","ACT","AMPY","DK","ATS","ECPG","MU","CYTK"],"gpt_icon":1},{"id":"2479643204","title":"Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2479643204","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479643204?lang=en_us&edition=fundamental","pubTime":"2024-10-29 01:23","pubTimestamp":1730136180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 13:23 ET (17:23 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2479436479","title":"Celldex selloff creates buying opportunity, says Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2479436479","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479436479?lang=en_us&edition=fundamental","pubTime":"2024-10-29 00:05","pubTimestamp":1730131532,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja notes that Celldex (CLDX) presented full data from the Phase 2 trial of barzolvolimab in two common forms of chroni...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-selloff-creates-buying-opportunity-says-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-selloff-creates-buying-opportunity-says-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.2072},{"period":"1month","weight":0.0442},{"period":"3month","weight":-0.2628},{"period":"6month","weight":-0.1777},{"period":"1year","weight":-0.0185},{"period":"ytd","weight":-0.2905}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.133197},{"month":2,"riseRate":0.421053,"avgChangeRate":-0.003124},{"month":3,"riseRate":0.473684,"avgChangeRate":0.006506},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.001523},{"month":5,"riseRate":0.289474,"avgChangeRate":-0.020325},{"month":6,"riseRate":0.487179,"avgChangeRate":0.148994},{"month":7,"riseRate":0.410256,"avgChangeRate":-0.015387},{"month":8,"riseRate":0.358974,"avgChangeRate":-0.028768},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023053},{"month":10,"riseRate":0.487179,"avgChangeRate":0.003931},{"month":11,"riseRate":0.564103,"avgChangeRate":0.059197},{"month":12,"riseRate":0.447368,"avgChangeRate":-0.007128}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}